Phaseline

Companies › Grand Shuyang Life Sciences (Chengdu)

Grand Shuyang Life Sciences (Chengdu): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Human Immunoglobulin (pH4) for Intravenous Injection (5%)
Intravenous immunoglobulin (IVIG) - polyclonal human antibodies that modulate immune respo
–Phase 3Primary Immune Thrombocytopenia (ITP)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07233213Human Immunoglobulin (pH4) for Intravenous Injection (5%)Phase 3Primary Immune Thrombocytopenia (ITP)HematologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Kedrion CSL Behring Incepta Pharmaceuticals Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.